Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells

Apr 21

Written By Lara Wilson

Sabharwal, S. et al. Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment Workshop 2022. April 21–22, 2022

Lara Wilson

A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

A First-In-Human Phase 1 Trial of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors